Huntington's Disease: An Interview with Dr. Burton Scott
Huntington's disease is a genetic disease that can have a devastating effect on a patient — physically, psychologically, and cognitively.
Irish Researchers Discover Potential Huntington's Disease Treatment
A European team of scientists discovered what they claim are encouraging early signs for a potential Huntington's disease (HD) treatment.
Cost-Effective Way to Diagnose Huntington's Disease Coming to Microsoft's Imagine Cup
Team NeuroGate will be competing in the Microsoft Imagine Cup finals with their work that recognizes neurodegenerative disorders like HD and Parkinson's.
Three UK Groups Push to Raise Awareness for Huntington's Disease
Three different groups from the United Kingdom are staying active this week in their efforts to raise awareness of and funds for Huntington's Disease research.
Data Network Will Assist in the Fight Against Huntington's Disease
The Huntington's Disease Network DataBase (HDNetDB) will potentially reduce the complexity by allowing scientists to freely share data.
This Week in JAMA: Huntington's Patients Can Safely Switch to Austedo Tablets
Results from the ARC-HD study were published, and showed that patients can easily switch from tetrabenazine to the recently approved Austedo.
Great-Granddaughter of Sigmund Freud To Give Poetry Reading for Huntington's Disease
Annie Freud, great-grandaughter of Sigmund, will be giving a poetry reading in an effort to raise funds for the Huntington's disease association.
Study Discovers New Gene Responsible for Huntington's Disease Progression
Per a British study published in Lancet Neurology, mutations of the MSH3 gene may be associated with Huntington's disease (HD) progression.
Triple Threat: HD Patient Researches, Educates and Advocates
He's a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
IONIS-HTT Rx Study in HD Patients Completes Enrollment
Ionis the completion of enrollment in its Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRs in Huntington's Disease patients.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.